THE CORPORATE DIRECTORY - Walker's 2007

Business: The company's principal activity is to develop and market biologically based solutions for the repair and replacement of damaged or inadequate human tissues in different clinical applications. The company's tissue matrix technology removes all cells from the tissue and preserves the tissue without damaging the essential biochemical and structural components necessary for normal tissue regeneration. The products of the company include: alloderm(R) for plastic reconstructive, burn and periodontal procedures; cymetra(tm) for non-surgical correction of soft tissue defects; repliform(tm) for urology and gynecology procedures; cryopreserved allograft skin for use as a temporary wound dressing in the treatment of burns; cymetra (R), a version of alloderm in particulate form; repliform(R) for urogynecologic procedures; graft jacket(R) for orthopedic applications and allocrat f (TM) dbm for bone grafting. Primary SIC and add'I.: 2836 8731

CIK No: 0000849448

Officers: Bradly C. Tyler/Controller, David J. Mcquillan/VP - Research, Paul G. Thomas/Chmn., Pres., CEO/\$416,042.00, Steven T. Sobieski/VP - Finance, Administration, CFO/\$232,000.00, Lisa N. Colleran/Sr. VP - Commercial Operations/\$260,750.00, Bruce Lamb/Sr. VP - Development, Regulatory Affairs, Quality/\$176,250.00, John R. Harper/VP - Clinical Sciences, Young C. Mcguinn/VP - Manufacturing Operations/\$213,825.00

Directors: Michael R. Minogue/Dir., Member - Nominating - Corporate Governance Committee, Paul G. Thomas/Chmn., Pres., CEO, David Fitzgerald/Dir., Member - Nominating - Corporate Governance Committee, Member - Compensation Committee, Member - Audit Committee, Martin P. Sutter/Dir., Chmn. - Nominating - Corporate Governance Committee, Presiding Dir., Robert P. Roche/Dir., Member - Compensation Committee, James G. Foster/Dir., Member - Audit Committee, Chmn. - Compensation Committee, Michael E. Cahr/Dir., Chmn. - Audit Committee

Owners: Lisa N. Colleran, Arbor Capital Management, LLC/6.10%, David Fitzgerald, Michael E. Cahr, Young C. McGuinn, Paul G. Thomas/1.20%, Steven T. Sobieski, Bruce Lamb, James G. Foster, Barclays Global Investors, N.A./6.40%, Martin P. Sutter

Financial Data: Fiscal Year End: 12/31 Latest Annual Data: 12/31/2005

Year	Sales			Net Ir	ncome
2005	\$94,398,000			\$12,0	44,000
2004		\$61,127,000		\$7,1	84,000
2003	\$40,249,000			\$18,6	72,000
Curr. Assets:	\$87,934,000	Curr. Liab.:	\$14,725,000	P/E Ratio:	44.75
Plant, Equip.:	\$9,271,000 Total Liab.: \$14,928,000 In			Indic. Yr. Divd.:	NA
Total Assets:	\$106,998,000	Net Worth:	\$92,070,000	Debt/ Equity:	NA

Lifecore Biomedical Inc

3515 Lyman Blvd, Chaska, MN, 55318; PH: 1-952-368-4300; Fax: 1-952-368-3411;

3515 Lyman Bivu, Chasad, Mar, 2007., http://www.lifecore.com; *Email:* info@lifecore.com Stock: Price General - Inco 10/00/00/0

ore.com, <i>Linuu</i> . mio@meeore.com	
orporation MN	Stock - Price on:12/22/2006\$16.36
	Stock ExchangeNDQ
Grant Thornton LLP	Ticker Symbol LCBM
Wells Fargo Bank Minnesota	Outstanding Shares
Dorsey & Whitney LLP	E.P.S\$0.52
	Shareholders

Business: The group's principal activities are to manufacture biomaterials and medical devices for use in various surgical markets and to provide related specialized contract aseptic manufacturing services. The group operates in two divisions: the hyaluronan division and the oral restorative division. The hyaluronan division develops and manufactures products utilizing hyaluronan, a naturally occurring carbohydrate that moisturizes the body tissues. The products are marketed through OEM and contract manufacturing alliances in gynecologic and ophthalmologic surgery and veterinary medicine. The oral restorative division develops and markets precision surgical and prosthetic devices for the restoration of damaged dentition and associated support tissues and markets its products through direct sales in the United States, Italy, Germany, Sweden and through distributors in other foreign countries. Primary SIC and add'I.: 3842 3841 3843

CIK No: 0000028626

Employees Auditor

Stk Agt.

Counsel.

DUNS No

Subsidiaries: Implant Support Systems, Inc., Lifecore Biomedical GmbH, Lifecore Biomedical SpA, Lifecore Biomedical, AB, Lifecore Biomedical, SAS, Sustain, Inc.

Officers: Joan L. Gardner/Dir. - Governance, Nominating Committee, the Compensation Committee, David M. Noel/VP - Finance, CFO/\$145,000.00, Dennis J. Allingham/Dir., Pres., CEO, Sec./\$300,000.00, James G. Hall/VP - Technical Operations, Ben C. Beckham/VP - ORD Sales, Marketing/\$175,632.00, Kipling Thacker/VP - New Business Development/\$130,000.00, Larry D. Hiebert/VP, GM - Hyaluronan Division/\$145,000.00

Directors: Martin J. Emerson/Dir., Orwin L. Carter/Dir. - Audit Committee, the Governance, Nominating Committee, Joan L. Gardner/Dir. - Governance, Nominating Committee, the Compensation Committee, John E. Runnells/Lead Dir., Chmn. - Governance - Nominating Committee, Thomas H. Garrett/Dir., Chmn. - Compensation Committee, Dennis J. Allingham/Dir., Pres., CEO, Sec., Richard W. Perkins/Dir. - Audit Committee, Compensation Committee, Luther T. Griffith/Dir., Chmn. - Audit Committee, Member - Governance - Nominating Committee

Owners: Benjamin C. Beckham, Dennis J. Allingham/2.60%, Thomas H. Garrett, David M. Noel, Carnegie Investment Bank AB/7.70%, Larry D. Hiebert, Richard W. Perkins/1.40%, Joan L. Gardner, Luther T. Griffith, John E. Runnells, Kipling Thacker, The Vertical Group, L.P./10.10%, Orwin L. Carter

Financial Data: Fiscal Year End:06/30	Latest Annual Data: 06/30/2006
---------------------------------------	--------------------------------

Year		Sales		Net Income
2006		\$63,097,000		\$7,040,000
2005		\$55,221,000		\$17,511,000
2004		\$47,036,000		\$707,000
Curr. Assets:	\$57,368,000	Curr. Liab.:	\$6,898,000	P/E Ratio: 44.75
Plant, Equip.:	\$24,656,000	Total Liab.:	\$11,702,000	Indic. Yr. Divd.: NA
Total Assets:	\$89,238,000	Net Worth:	\$77,536,000	Debt/ Equity: 0.0596

Lifeline Therapeutics Inc

Suite 1970, 6400 S. Fiddlers Green Circle, Englewood, CO, 80111; PH: 1-720-488-1711; Fax: 1-720-488-1722: http:// www.lifelinetherapeutics.com: Email: info@protandim.com

1 aut 1 /20 100 1/22, mpin a a antenietapea	interesting and the opposite of the opposite o
General - IncorporationCO	Stock- Price on: 12/22/2006\$0.6
Employees	Stock ExchangeOTC
Auditor Gordon, Hughes & Banks LLP	Ticker Symbol LFLT.OB
Stk Agt Computershare	Outstanding Shares
CounselNA	E.P.S\$0.16
DUNS No	Shareholders279

Lifestream Technologies Inc - 969

Business: The group's principal activity is to seek business combinations with one or more existing private business enterprises. The group was in the business of mining of gold, other precious and base metal. Its efforts to pursue as a mining industry failed and the group resolved to sell its mining properties. The group is in development stage

Primary SIC and add'I.: 9999

CIK No: 0000849146

Subsidiaries: Lifeline Nutraceuticals Corporation, Lifeline Nutraceuticals, Inc

Officers: Joe Mccord/Dir. - Science, Leigh Severance/Independent Dir., Member - Audit Committee, Chairperson - Compensation Committee, Nominating Committee, Michael Blakeman/Sr. VP - Sales - Marketing, Gerald J. Houston/CFO, Sec./\$95,000.00, Stephen K. Onody/Dir., CEO/\$166,564.00

Directors: William L. Lister/Independent Dir., Member - Compensation Committee, Javier Baz/Independent Dir., Chmn., Member - Compensation Committee, Leigh Severance/Independent Dir., Member - Audit Committee, Chairperson - Compensation Committee, Nominating Committee, James Crapo/Independent Dir., John B. Van Heuvelen/Independent Dir., Member - Compensation Committee, Stephen K. Ondy/Dir, CEQ, Jim Krejci/Independent Dir., Meines J. Krejci/65/Dir., Member - Audit Committee - Nominating Committee, Larry Gold/66/Dir.

Owners: Paul R. Myhill/12.90%, Daniel W. Streets/7.70%, William L. Lister, John B. Van Heuvelen, Joe M. McCord/7.30%, Brenda March, Javier W. Baz/5.00%, William J. Driscoll/16.20%, Stephen K. Onody/1.50%, James D. Crapo/2.80%, Larry Gold, Leigh H. Severance/4.90%, James J. Krejci . . .

Financial Data: Fisca	I Year End:06/30 Latest Annual Data:	06/30/2006
Year	Sales	Net Income
2006	\$7,166,000	-\$2,735,000
2005	\$2,354,000	-\$5,822,000
2004	\$0	-\$453.441.000

2005		\$2,354,000		-\$5,822,000
2004		\$0		-\$453,441,000
Curr. Assets:	\$2,000	Curr. Liab.:	\$14,000	
Plant, Equip.:	NA	Total Liab.:	\$14,000	Indic. Yr. Divd.: NA
Total Assets:	\$38,000	Net Worth:	\$23,000	Debt/ Equity: 0.0006

Lifepoint Hospitals Inc

103 Powell Ct, Ste 200, Brentwood, TN, 37027; **PH:** 1-615-372-8500;

http:// www.lifepointhospitals2.com; Email: general.information@lifepointhospitals.com					
General - Incorporation					
Employees		Stock Exchange	NDQ		
A 114		m: 1 0 1 1	I DUT		

Employees		Stock Exchange	NDQ
Auditor	Ernst & Young LLP	Ticker Symbol	LPNT
Stk Agt	National City Bank	Outstanding Shares	
Counsel	NA	E.P.S	\$2.33
DUNS No	NA	Shareholders	5,040
Pucinocc: The		and the second second second sector to the second	and a second second second

Siness: The group's principal activity is to provide acute care hospitals in non-urban communities The hospitals provide a broad range of medical and surgical services. They also provide diagnostic and emergency services, as well as outpatient and ancillary services including outpatient surgery, laboratory, rehabilitation, radiology, respiratory therapy and physical therapy. At 01-Mar-2004 the group operated 29 hospitals with 2,727 licensed beds in the non-urban communities. The group has hospitals located in Alabama, Florida, Kansas, Kentucky, Louisiana, Tennessee, Utah, west Virginia and Wyoming. On 01-10-2003, the group acquired the 75-bed spring view hospital in lebanon, Kentucky and on 01-07-2004 the group acquired 106-bed river parishes hospital in laplace, Louisiana.

Primary SIC and add'I.: 6324 8062

CIK No: 0001074772

Subsidiaries: 118 Subsidiaries included in the Index

Officers: Bill Truex/Experienced Technical Difficulties, Todd Wiltsie/Physician Recruitment, Michael J. Culotta/CFO, William M. Gracey/COO, Kenneth C. Donahey/Chmn, Chief Executiv Officer, Pres., William F. Carpenter/CEO, Dir., Pres., Mark Dupay/Corporate, Executive Recruitment, Penny Brake/Investor Relations

Directors: John E. Maupin/Dir., Ricki Tigert Helfer/Dir., Michael P. Haley/Dir., William V. Lapham/Dir., Dewitt Ezell/Dir., Owen G. Shell/Chmn., Kenneth C. Donahey/Chmn., Chief Executiv

Officer, Pres., William F. Carpenter/CEO, Dir., Pres., Richard H. Evans/Dir. Financial Data: Fiscal Year End: 12/31 / atest Annual Data: 12/31

Financial Data. Fiscal fedi Enu.12/31 Latest Annual Data. 12/31/2003					
Year		Sales	;	Net Ir	ncome
2005		\$1,855,100,000)	\$72,9	00,000
2004		\$996,900,000)	\$85,7	'00,000
2003		\$907,100,000)	\$68,5	00,000
Curr. Assets:	\$421,600,000	Curr. Liab.:	\$230,100,000	P/E Ratio:	14.63
Plant, Equip.:	\$1,302,300,000	Total Liab.:	\$1,936,800,000	Indic. Yr. Divd.:	NA
Total Assets:	\$3,224,600,000	Net Worth:	\$1,287,800,000	Debt/ Equity:	1.2532

Lifestream Technologies Inc

570 Clearwater Loop, Bldg 1000, Ste D, Post Falls, ID, 83854; PH: 1-208-457-9409;

Fax: 1-208-457-9509; http	:// www.lifestreamtech.c	com; Email: sales2@lifestreamtec	h.com		
General - Incorporation	1NV	Stock- Price on:12/22/2006	\$0.0002		
Employees	11	Stock Exchange	OTC		
Auditor	BDO Seidman LLP	Ticker Symbol	LFTC.PK		
Stk Agt	Nevada Agency	Outstanding Shares			
Counsel	NA	E.P.S	\$0.017		
DUNS No.	NA	Shareholders			
Business: The group's principal activity is to develop manufacture and market proprietory amont					

Business: The group's principal activity is to develop, manufacture and market proprietary smart card-enabled medical diagnostic devices. These devices are used to prevent, detect, monitor and control cholesterol. The diagnostic product line consists of hand-held card-enabled cholesterol monitors. The consumer device is designed for use at home by the consumers at-risk, cholesterol patients and health conscious consumers. The other products are designed for point-of-care facility-use by various medical professionals and pediatricians. The group markets through national and regional drug store chains, pharmacy-featuring grocery store chains, specialty catalog and Internet-based direct marketers and independent pharmacies

Primary SIC and add'I.: 3841 5047

CIK No: 0001029738

Subsidiaries: Lifestream Diagnostics, Inc., Secured Interactive Technologies, Inc. Officers: Shirley Vesser/Dir. - Customer Services, Robert F. Boyle/Dir., Sec., Christopher T. Maus/Chmn., Pres., CEO/\$150,577.00, Matt Colbert/Dir., VP - Finance

Directors: Michael Crane/51/Dir., Ed Siemens/Dir., Robert F. Boyle/Dir., Sec., Neil Luckianow/Dir., Christopher T. Maus/Chmn., Pres., CEO, Matt Colbert/Dir., VP - Finance